American cell and gene therapy company
President and CEO Sandy Macrae in 2018
Sangamo Therapeutics, Inc. (previously known as Sangamo Biosciences, Inc. ) is an American biotechnology company based in
Brisbane , California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
[2]
History
The company was founded in 1995 in Richmond, California.
[3] It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees.
[3] Sandy Macrae is the president.
[4] In 2018,
Edward Rebar became the senior vice president and chief technology officer of Sangamo.
[5]
Research
Sangamo applies technology to treat
haemophilia B and
lysosomal storage diseases including
mucopolysaccharidosis type I (Hurler Syndrome) and
mucopolysaccharidosis type II (Hunter Syndrome). The
FDA granted Sangamo
fast track designation for SB-525, a gene therapy candidate for
haemophilia A . In its partnership with
Pfizer in 2017,
[6] Sangamo uses
Bioverativ in
hemoglobinopathies such as
beta thalassemia and
sickle cell disease .
[2] It is also developing
zinc finger gene editing technology.
[7]
In February 2019, medical scientists, working with Sangamo Therapeutics, announced the first ever "in body"
human gene editing therapy to permanently alter
DNA - in a patient with
Hunter syndrome .
[8] As of February 2019
[update] clinical trials by Sangamo involving gene editing using
zinc finger nuclease were ongoing.
[9]
Clinical trials
Sangamo's programs are a mix of wholly owned and partnered; major partners include
Pfizer ,
Biogen ,
Sanofi ,
Takeda , and
Kite (a
Gilead company).
[10]
[2]
[11]
[12]
As of 2020 Sangamo had the following clinical trials underway in the US:
In February 2023, Sangamo Therapeutics announced that it would stop the late-stage development for the Phase 1/2 PRECIZN-1 study of BIVV003 its sickle cell drug.
[20]
See also
References
^
a
b
c
d
e
f
"Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results" . Sangamo. February 22, 2023. Retrieved February 24, 2023 .
^
a
b
c McConaghie, Andrew (May 17, 2017).
"Sangamo and new gene therapy partner Pfizer lifted by FDA fast track" . Pharmaphorum . Retrieved October 1, 2018 .
^
a
b
"Sangamo Therapeutics Inc. (SGMO) Moves Higher on Volume Spike for September 04" . Equities . September 8, 2018. Retrieved October 1, 2018 .
^ Ledford, Heidi (September 5, 2018).
"First test of in-body gene editing shows promise" . Nature .
doi :
10.1038/d41586-018-06195-6 .
ISSN
0028-0836 .
S2CID
92840885 .
^
"Sangamo Therapeutics appoints Edward Rebar as senior vice president" . Post Online Media . Richmond, California. July 16, 2018. Retrieved October 1, 2018 .
^
"SANGAMO THERAPEUTICS AND PFIZER ANNOUNCE COLLABORATION FOR HEMOPHILIA A GENE THERAPY | Pfizer" . www.pfizer.com . Retrieved April 22, 2020 .
^ Renauer, Cory (September 6, 2018).
"Sangamo's Zinc Fingers Fail Again. Time to Walk Away?" . The Motley Fool . Retrieved October 1, 2018 .
^ Marchione, Marilyn (February 7, 2019).
"Tests suggest scientists achieved 1st 'in body' gene editing" .
AP News . Retrieved February 7, 2019 .
^ Staff (February 2, 2019).
"Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II" .
ClinicalTrials.gov .
U.S. National Library of Medicine . Retrieved February 7, 2019 .
^ Reuters Editorial.
"SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters" . SGMO.OQ - Sangamo Therapeutics Inc Profile | Reuters . Retrieved July 28, 2020 .
^
"Sangamo shares jump on Pfizer, Sanofi (and its own) gene, cell therapy updates" . FierceBiotech . Retrieved July 29, 2020 .
^
"Exciting new Huntingtin lowering tool described - HDBuzz - Huntington's disease research news" . en.hdbuzz.net . Retrieved July 29, 2020 .
^
"A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT) - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"Dose-Ranging Study of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B - Full Text View - ClinicalTrials.gov" . clinicaltrials.gov . Retrieved July 28, 2020 .
^
"Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans" . Fierce Biotech . February 23, 2023. Retrieved February 24, 2023 .
External links
37°40′36″N 122°23′03″W / 37.67669°N 122.38421°W / 37.67669; -122.38421